Amgen (AMGN) to Release Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN) will likely be announcing its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of $5.01 per share and revenue of $8.9821 billion for the quarter. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the company earned $4.97 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, analysts expect Amgen to post $21 EPS for the current fiscal year and $21 EPS for the next fiscal year.

Amgen Trading Up 2.2%

NASDAQ AMGN opened at $298.43 on Friday. The firm has a market capitalization of $160.66 billion, a P/E ratio of 24.40, a PEG ratio of 2.61 and a beta of 0.49. The business has a fifty day simple moving average of $287.75 and a 200 day simple moving average of $287.46. Amgen has a 12 month low of $253.30 and a 12 month high of $335.88. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president directly owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.76% of the company’s stock.

Institutional Trading of Amgen

Hedge funds and other institutional investors have recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC raised its stake in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the period. Ieq Capital LLC lifted its holdings in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after purchasing an additional 2,611 shares in the last quarter. U S Wealth Group LLC. boosted its stake in Amgen by 4.3% in the 2nd quarter. U S Wealth Group LLC. now owns 7,832 shares of the medical research company’s stock worth $2,187,000 after purchasing an additional 321 shares during the period. Finally, Diversify Advisory Services LLC grew its holdings in Amgen by 60.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 10,738 shares of the medical research company’s stock valued at $3,060,000 after buying an additional 4,032 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMGN shares. Weiss Ratings upgraded shares of Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 27th. Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating for the company. Citigroup lifted their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Finally, Piper Sandler raised their target price on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $300.94.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.